For people hoping that Big Pharma Could still be barred from the medical-marijuana scene there is bad news: the agreement is done. Keep your eyes open for the first naturally derived, Big Pharma develops marijuana products to be released to the public to purchase the frosted half of 2016, perhaps even sooner.
Epidiolex is a liquid formulation of pure, plant derived cannabidiol, developed by the British company, G.W. Pharmaceuticals. It is as now on the FDA Fast Track ad has entered its last Phase 3 testing for pediatric epilepsy disorders such as Dravet’s and Lennox-Gastaut’s syndromes with results scheduled for the first quarter of 2016.
Dealing with an unlikely catastrophic discovery, there are many indicators that Epidiolex will breeze through this last stage and will thus have hurdled the FDA’s testing standards. For various different drugs, the remaining details would be purely administrative yet Epidiolex is derived from marijuana and that puts a few more obstacles in the way before marketing can start. There are, however, a good amount of signs that government officials are currently making a way for this new player.
Among the most crucial happened on June 24, 2015. Prior to a full hearing room, the U.S. Senate Caucus on International Narcotics Control, starting back from 1985 to “expand international cooperation against drug abuse and narcotics trafficking” took on the decidedly domestic problem of what to do about medical marijuana. The conference was chaired by two unlikely medical marijuana supporters, Senators Charles Grassley and Dianne Feinstein.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com